Mealey's (February 28, 2023, 10:19 AM EST) -- WASHINGTON, D.C. — A federal judge in Delaware did not abuse his discretion in directing a patent owner to delist its patent from the U.S. Food and Drug Administration’s Approved Drug Products with Therapeutic Equivalence Evaluations publication, the Federal Circuit U.S. Court of Appeals ruled, lifting a stay it entered in November....